CCHT(SZ:000661) Zheng Quan Shi Bao Wang·2025-09-02 11:03Core Viewpoint - The company, Changchun High-tech (000661), announced significant developments regarding its innovative drug pipeline and plans for H-share issuance on the Hong Kong Stock Exchange, while cautioning investors about the inherent risks associated with drug development [1] Group 1: Company Developments - The company reported on its innovative drug, Jinbeixin (Fuxin Qibai monoclonal antibody), and highlighted key projects under research in its 2025 semi-annual report [1] - The company is in the process of issuing H-shares and applying for listing on the main board of the Hong Kong Stock Exchange, with related procedures and work progressing smoothly [1] - There have been no significant changes in the company's operational conditions or external business environment recently [1] Group 2: Industry Context - The company emphasized the long cycle, high investment, and high uncertainty associated with innovative drug development, urging investors to be aware of the investment risks [1]